Literature DB >> 16111729

Clinical presentation of melioidosis in Queensland, Australia.

Agnieszka B Malczewski1, Kimberly M Oman, Robert E Norton, Natkunam Ketheesan.   

Abstract

A retrospective study was performed on culture-positive patients (n = 57) with melioidosis presenting to the Townsville Hospital to define the epidemiology of the disease in Queensland, Australia. Mortality was 25% (n = 14) with a 9% (n = 5) relapse rate. At presentation, primary organs involved included the lungs (58%; n = 33), genitourinary system (11%; n = 6), skin and soft tissue (9%; n = 5), bone and joints (4%; n = 2), central nervous system (4%; n = 2), mycotic aneurysm (2%; n = 1) and peritonitis (2%; n = 1). No focus of infection could be identified in 12% of cases (n = 7). There was no significant difference in the clinical presentation of melioidosis in Queensland compared with the Northern Territory. Regional trends in the clinical presentation of melioidosis in Australia compared with Southeast Asia were confirmed. Risk factors for disease included diabetes (42%), excess alcohol consumption (42%), chronic lung disease (26%), immunosuppressive drug use (12%), renal disease (11%), malignancy (7%) and autoimmune disease (5%). No risk factors were identifiable in 18% of cases. The presence of multiple risk factors for melioidosis was not significantly associated with increased mortality (P > 0.05).

Entities:  

Mesh:

Year:  2005        PMID: 16111729     DOI: 10.1016/j.trstmh.2005.06.015

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  15 in total

1.  Comparison of routine bench and molecular diagnostic methods in identification of Burkholderia pseudomallei.

Authors:  Kelly Hodgson; Cathy Engler; Brenda Govan; Natkunam Ketheesan; Robert Norton
Journal:  J Clin Microbiol       Date:  2009-03-11       Impact factor: 5.948

2.  Use of antigens derived from Burkholderia pseudomallei, B. thailandensis, and B. cepacia in the indirect hemagglutination assay for melioidosis.

Authors:  Glenda Gilmore; Jodie Barnes; Natkunam Ketheesan; Robert Norton
Journal:  Clin Vaccine Immunol       Date:  2007-09-05

3.  An 11-Year Analysis of Emergency Presentations of Melioidosis in Northeastern Malaysia.

Authors:  Mohd Boniami Yazid; Mohd Hashairi Fauzi; Habsah Hasan; Abu Yazid Md Noh; Zakuan Zainy Deris
Journal:  J Immigr Minor Health       Date:  2017-06

Review 4.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

5.  Evidence of Burkholderia pseudomallei-specific immunity in patient sera persistently nonreactive by the indirect hemagglutination assay.

Authors:  Patrick N A Harris; Natasha L Williams; Jodie L Morris; Natkunam Ketheesan; Robert E Norton
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

6.  Physicochemical factors affecting the growth of Burkholderia pseudomallei in soil microcosm.

Authors:  Supunnipa Wang-Ngarm; Sorujsiri Chareonsudjai; Pisit Chareonsudjai
Journal:  Am J Trop Med Hyg       Date:  2014-01-20       Impact factor: 2.345

7.  Rapid diagnostics for melioidosis: a comparative study of a novel lateral flow antigen detection assay.

Authors:  Gemma Robertson; Alanna Sorenson; Brenda Govan; Natkunam Ketheesan; Raymond Houghton; Hongjing Chen; David AuCoin; Michael Dillon; Robert Norton
Journal:  J Med Microbiol       Date:  2015-06-07       Impact factor: 2.472

8.  The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study.

Authors:  Bart J Currie; Linda Ward; Allen C Cheng
Journal:  PLoS Negl Trop Dis       Date:  2010-11-30

9.  Clinical features that affect indirect-hemagglutination-assay responses to Burkholderia pseudomallei.

Authors:  Patrick N A Harris; Natkunam Ketheesan; Leigh Owens; Robert E Norton
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

10.  Epidemiological and Clinical Features of Melioidosis: A Report of Seven Cases from Southern Inland China.

Authors:  Yanping Tang; Jingmin Deng; Jianquan Zhang; Xiaoning Zhong; Ye Qiu; Hui Zhang; Haiguang Xu
Journal:  Am J Trop Med Hyg       Date:  2018-03-29       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.